BioAge Labs Inc. (BIOA)
BioAge Labs Statistics
Share Statistics
BioAge Labs has 35.85M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 35.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 64.22% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.87 and the forward PE ratio is -1.58. BioAge Labs's PEG ratio is 0.04.
| PE Ratio | -0.87 |
| Forward PE | -1.58 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.19 |
| P/FCF Ratio | -1.2 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioAge Labs.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.86, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.86 |
| Quick Ratio | 12.86 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.08 |
| Debt / FCF | -0.12 |
| Interest Coverage | 33.04 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.15M |
| Employee Count | 62 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.5, so BioAge Labs's price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 4.08 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 56.32 |
| Average Volume (20 Days) | 245.26K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -78.19M |
| Net Income | -71.11M |
| EBITDA | -78.19M |
| EBIT | -73.48M |
| Earnings Per Share (EPS) | -6.63 |
Balance Sheet
The company has 354.35M in cash and 6.2M in debt, giving a net cash position of 348.15M.
| Cash & Cash Equivalents | 354.35M |
| Total Debt | 6.2M |
| Net Cash | 348.15M |
| Retained Earnings | -252.81M |
| Total Assets | 358.23M |
| Working Capital | 329.33M |
Cash Flow
In the last 12 months, operating cash flow was -51.52M and capital expenditures -366K, giving a free cash flow of -51.89M.
| Operating Cash Flow | -51.52M |
| Capital Expenditures | -366K |
| Free Cash Flow | -51.89M |
| FCF Per Share | -4.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BIOA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BIOA is $5, which is 19% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 19% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 3 |